<DOC>
	<DOCNO>NCT00635557</DOCNO>
	<brief_summary>This open-label , dose finding , multiple-dose study subject recurring/relapsing glioblastoma multiforme . Three dose level MPC-6827 administer carboplatin three separate cohort . Study endpoint include determination maximum tolerate dose , dose limit toxicity , evaluation evidence anti-tumor activity MPC-6827 give carboplatin .</brief_summary>
	<brief_title>Phase 1 Study MPC-6827 Carboplatin Recurrent/Relapsed Glioblastoma Multiforme</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically prove WHO Grade IV glioblastoma multiforme time diagnosis relapse Prior treatment radiotherapy temozolomide Evidence measurable recurrent residual primary tumor contrastenhanced MRI Be minimum 4 week since prior surgical resection , major surgical procedure , radiation therapy cytotoxic chemotherapy ( 6 week since prior BCNU CCNU ) Have Performance Scale Karnofsky &gt; 60 % , ECOG &lt; 2 WHO &lt; 2 If steroid need , stable decrease dose steroid least 1 week Hypersensitivity Cremophor EL Have evidence current/active intratumor hemorrhage MRI Have great second relapse Have prior treatment platinumbased chemotherapy Have cardiovascular disease Have cerebrovascular disease Have uncontrolled hypertension Have cardiac ejection fraction &lt; 50 % Have TroponinI elevate normal range</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Recurrent</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Glioblastoma</keyword>
	<keyword>Multiforme</keyword>
</DOC>